MedTrace Logo

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

NCT07381829 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2026-02-02

No results posted yet for this study

Summary

Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced lung cancer and determine the recommended dose for subsequent studies.

Conditions

  • Advanced Solid Tumor Cancer

Interventions

DRUG

HC010

HC010 once every 3 weeks (Q3W) by intravenous drip

DRUG

Paclitaxel (Chemotherapy)

the combination chemotherapy regimens are all commonly used in clinical practice

DRUG

Pemetrexed

the combination chemotherapy regimens are all commonly used in clinical practice

DRUG

Etoposide

the combination chemotherapy regimens are all commonly used in clinical practice

DRUG

Carboplatin/Cisplatin

the combination chemotherapy regimens are all commonly used in clinical practice

DRUG

Docetaxel

the combination chemotherapy regimens are all commonly used in clinical practice

Sponsors & Collaborators

  • HC Biopharma Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-27
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07381829 on ClinicalTrials.gov